Monica Balzarotti
A5024161871- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Multiple and Secondary Primary Cancers
- Acute Lymphoblastic Leukemia research
- Glioma Diagnosis and Treatment
- Frailty in Older Adults
- Sarcoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
- Cardiac tumors and thrombi
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
- Esophageal Cancer Research and Treatment
- Neutropenia and Cancer Infections
Humanitas University
2014-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
IRCCS Humanitas Research Hospital
2019-2025
Fondazione Humanitas per la Ricerca
2011-2022
Alessandro Manzoni Hospital
2020
University of Debrecen
2019
Medica (Italy)
1999-2019
Fondazione Intergruppo Italiano Linfomi Onlus
2012-2017
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2015
Policlinico S.Orsola-Malpighi
2014
To determine clinical features and patterns of outcome primary testicular diffuse large B-cell lymphomas (DLCL).A retrospective international survey 373 patients with DLCL.Most presented localized disease (stage I to II), the median age at diagnosis was 66 years (range, 19 91 years). Anthracycline-based chemotherapy administered 255 (68%), prophylactic intrathecal given 68 (18%); 133 (36%) received scrotal radiotherapy. Median overall survival 4.8 years, progression-free 4 years. The curves...
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Background and Objectives Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin’s lymphoma. Results of a new induction regimen are reported terms response rates, toxicity, stem cell mobilization.Design Methods Ninety-one patients with lymphoma were treated prospectively consisting ifosfamide 2000 mg/m2 on days 1 4, gemcitabine 800 vinorelbine 20 day 1, prednisolone 100 mg 4 (IGEV).Results Forty-nine (53.8%)...
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS, and extranodal sites. To prevent these events, we designed an international phase II trial (International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility activity of conventional chemoimmunotherapy associated CNS prophylaxis testis irradiation. The was conducted by the IELSG Italian Foundation. Patients Methods Fifty-three patients (age 22 to 79 years) untreated...
PURPOSE This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment MOPP and ABVD. Response salvage treatments prognostic factors also evaluated. PATIENTS AND METHODS The population included 115 refractory among a total of 415 treated alternating hybrid MOPP-ABVD followed by radiotherapy (25 30 Gy) initial bulky sites. median follow-up duration the present series was 91 months. Thirty-nine (34%) showed progression...
To assess the role of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) after rituximab and anthracycline-containing chemoimmunotherapy in patients with primary mediastinal large B-cell lymphoma (PMLBCL).Among 125 prospectively enrolled, 115 were eligible for central review PET/CT scans at completion standard chemoimmunotherapy, by using a five-point scale. Consolidation radiotherapy (RT) was permitted given to 102 patients.Fifty-four (47%) achieved...
abstract Learning Objectives After completing this course, the reader will be able to: Use a modulation of chemotherapy according to modified geriatric assessment improve outcomes for elderly patients with diffuse large B-cell lymphoma an acceptable level toxicity.Offer best tailored treatment while minimizing dose-limiting toxicity. CME This article is available continuing medical education credit at CME.TheOncologist.com Chemotherapy associated toxicity in potentially curable malignancies,...
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin’s lymphoma although half of patients relapse after transplantation. Predictive factors, such as within 12 months, Ann-Arbor stage at relapse, and in previously irradiated fields are classically used to identify with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged a new method providing information predict...
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis irradiation eliminates recurrences reduces relapses. The IELSG30 phase 2 study investigated feasibility activity an intensified IT IV prophylaxis. Patients stage I/II PTL who had not received treatment cycles high-dose methotrexate (MTX) (1.5 g/m2) after 6 the R-CHOP regimen (rituximab,...
PURPOSE The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. METHODS IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted PMBCL complete metabolic response (CMR) after induction immunochemotherapy. end point was progression-free survival (PFS) at 30 months random assignment. Patients CMR were randomly assigned observation or (30 Gy). With margin 10% (assuming 30-month PFS 85% both...
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma a Phase II trial. With response rates of 76% after and 83% without therapy, this was an active strategy, particularly low- to intermediate-risk (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression the dose-limiting toxicity, 9.5% lethal complications. After median follow-up 49 months, plateau survival curve...
Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone.In this prospective, multicenter, phase II study, patients relapsed/refractory who were not eligible for, or had relapsed after, intensive treatments received 25 mg/day (days 1-21 each 28-day cycle) dexamethasone (40 on days 1, 8, 15, 22) for up to 12 months.The primary end-points, overall complete response rates, achieved by 17 33 (52%; 95%...
This retrospective study included 246 patients with a new diagnosis of Hodgkin Lymphoma (HL) localized-stage (IA-IIA), consecutively admitted from January 2002 to December 2008, by twelve Italian hematological centers on behalf Fondazione Italiana Linfomi (FIL). Patients were staged at baseline and after two cycles chemotherapy PET. All treated four ABVD followed involved-field radiotherapy. No treatment change, based PET-2 results was allowed. Endpoint the predictive role 2-y failure-free...